Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 25, 2013

Primary Completion Date

October 3, 2018

Study Completion Date

October 3, 2018

Conditions
Lymphoma
Interventions
DRUG

Carfilzomib

"Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of Cycles 1-12. Cycles 13 and beyond, dose given on Days 1, 2, 15, and 16.~Phase II Starting Dose: MTD from Phase I."

DRUG

Lenalidomide

Phase I and Phase II: 20 mg by vein on Days 1-21 of each cycle.

DRUG

Rituximab

Phase I and II: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Celgene

INDUSTRY

collaborator

Onyx Therapeutics, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER